Australia markets close in 2 hours 41 minutes

Scopus BioPharma Inc. (SCPS)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0021+0.0010 (+90.91%)
At close: 11:06AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 88.38k
Enterprise value -273.72k
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.42
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.12

Trading information

Stock price history

Beta (5Y monthly) 0.25
52-week change 3-95.96%
S&P500 52-week change 329.31%
52-week high 30.1000
52-week low 30.0002
50-day moving average 30.0016
200-day moving average 30.0269

Share statistics

Avg vol (3-month) 31.81k
Avg vol (10-day) 33.08k
Shares outstanding 542.08M
Implied shares outstanding 642.08M
Float 834.22M
% held by insiders 118.69%
% held by institutions 10.00%
Shares short (30 Nov 2022) 423.77k
Short ratio (30 Nov 2022) 40.22
Short % of float (30 Nov 2022) 40.25%
Short % of shares outstanding (30 Nov 2022) 40.11%
Shares short (prior month 31 Oct 2022) 419.47k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 June 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-538.06%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -9.34M
Net income avi to common (ttm)-8.7M
Diluted EPS (ttm)-0.3100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)362.1k
Total cash per share (mrq)0.01
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)0.05
Book value per share (mrq)-0.24

Cash flow statement

Operating cash flow (ttm)-3.04M
Levered free cash flow (ttm)490.41k